Related Experiment Videos
Malaria associated anaemia, drug resistance and antimalarial combination therapy
1Division of Infectious Diseases, Department of Medicine, Karolinska Hospital, SE-17176 Stockholm, Sweden. anders.bjorkman@ks.se
Insights
Malaria-associated anaemia is a leading cause of childhood death in Africa. New combination antimalarial therapies are needed to combat drug resistance and effectively clear parasites, preventing severe childhood anaemia.
Area of Science:
- Infectious Diseases
- Hematology
- Pharmacology
Background:
- Malaria-associated anaemia is a significant cause of mortality in children in sub-Saharan Africa.
- Effective prevention requires prompt treatment of high parasitaemia and reduction of asymptomatic infections to allow erythrocyte recovery.
- Antimalarial drug resistance is increasingly compromising these interventions.
Purpose of the Study:
- To propose a novel treatment strategy for malaria-associated anaemia.
- To address the challenge of reduced antimalarial drug efficacy due to parasite resistance.
- To outline the need for drug combinations with optimal pharmacokinetic and pharmacodynamic properties.
Main Methods:
- This study proposes a conceptual approach based on existing knowledge of malaria and drug resistance.
- It emphasizes the need for strategic drug combinations.
- Focus is on optimal pharmacodynamic and kinetic properties of antimalarials.
Main Results:
- A new treatment strategy involving drug combinations is proposed.
- This strategy aims for rapid and complete parasite clearance.
- It also aims to provide temporary protection against re-infection and prevent further drug resistance.
Conclusions:
- Combination antimalarial therapy is essential to overcome drug resistance.
- Optimized drug combinations can achieve rapid parasite clearance and prevent severe anaemia.
- This approach is crucial for reducing childhood mortality in malaria-endemic regions.
Abstract:
Malaria associated anaemia represents a major cause of childhood mortality in sub-Saharan Africa. Prevention of severe anaemia necessitates rapid treatment of symptomatic high density parasitaemia, as well as reduction of asymptomatic parasite prevalence to provide recovery period to restore production of erythrocytes. Both interventions are being increasingly impaired by reduced efficacy of antimalarial treatment due to parasite drug resistance. A new treatment strategy, including combinations of antimalarial drugs with optimal pharmacodynamic and kinetic properties may respond to the need of rapid and radical parasite clearance, temporary protection to re-infection, and prevention of drug resistance.